William Ho

Biotech investor and entrepreneur advancing novel therapies for cancer & autoimmune diseases; ex-Wall Streeter and VC. Co-founder and CEO of @IN8bio

[William Ho @willhonyc]

@andrewpannu TCE - much appreciated!

[William Ho @willhonyc]

Very pleased to welcome Oxana Polyakova to @IN8bio as our new SVP of R&D.

Her deep experience in gamma-delta T cells and T cell engagers will be invaluable as we advance INB-619 and our broader platform.

$INAB

[William Ho @willhonyc]

@Jlindig0 @DrSynbio Haha…a Board member once asked why I knew how many milliliters our culture chambers were.

[William Ho @willhonyc]

@AppleHelix There are only a few of us, the founder-entrepreneurs in biotech today. I think it's structural with VC's, the size of funds and ultimately control. Cost makes it difficult to bootstrap a biotech that's truly innovative and it involves an extraordinary amount of suffering.

[William Ho @willhonyc]

@_indexmatch_ @BoringBiz_ As someone said to me years ago when I was just starting out as an Associate in IB, “if you’re going to play, you should go to where the big boys are.” NYC still better in finance.

[William Ho @willhonyc]

@MarioNawfal @MarioNawfal – It’s certainly an exciting area of biology, one that our team @IN8bio has been focused on for decades! You’re welcome to visit our labs anytime to check out the work we’re doing!

[William Ho @willhonyc]

Exactly! This is the biology we’re building @IN8bio around. So much potential!

[Mario Nawfal @MarioNawfal]

NEW FRONT IN THE WAR ON CANCER: THE CELLS THAT DON’T PLAY BY THE RULES

Forget the T cells you know. There’s a rogue branch of the immune system - γδ T cells - and they’re not waiting for your MHC permission slip.

These cells don’t need to “see” cancer the old-fashioned way.

They hunt by instinct - detecting stress, mutation, and molecular chaos where αβ T cells see nothing.

Think of them as the immune system’s black ops, trained to strike tumors that hide from mainstream defenses.

The kicker? They can be mass-produced from healthy donors.

No bespoke cell cocktails, no waiting for weakened patients to donate their own.

“Off-the-shelf” soldiers, ready to deploy.

Early trials show they kill tumors, boost immune memory, and even help repair damage - all without torching healthy tissue.

γδ T cells could do what αβ therapies can’t: take the fight to every cancer, in every body, without the side effects that make remission feel like survival’s fine print.

The next generation of immunotherapy isn’t coming from a lab - it’s been sitting in our blood all along.

Source: Science, Hayday et al.

[William Ho @willhonyc]

LOL…as an ex-investor that spent 17 years on Wall St before operating full-time, most investors would be shocked at what it takes just to keep the “wheels on the bus” moving forward without having them falling off! It would blow most people’s mind to see the stuff that goes sideways. Sometimes you’re just like, “How on Earth!?!” I know I was humbled for sure!

[William Ho @willhonyc]

@In8bio 🇺🇸 Happy 4th to all!

[William Ho @willhonyc]

@Nfcanavan Beautiful! Where’s that!?!

[William Ho @willhonyc]

Exciting data from our Phase 1 INB-200 program presented in an oral session this weekend at ASCO2025! I heard great feedback from KOLs across the country as we try to make a real impact for these patients with GBM. Please join us on a conference call at 8:30am EDT as we review the data where median PFS for patients receiving repeated doses surpassed historical median OS for standard-of-care.

[IN8bio @In8bio]

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed
GBM Demonstrating Prolonged Progression-Free Survival.

Join us today, June 2nd at 8:30 am, for a company conference call to discuss the data with IN8bio management and Dr. Burt Nabors, the lead clinical investigator.

Read the full press release for the webcast link: https://t.co/YLRBznq0Hv.

$INAB #ASCO2025 @ASCO #ASCO2025 #GDTcells #GammaDeltaTCells

[William Ho @willhonyc]

@Nfcanavan Hey! How have you been? What are you up to now?

[William Ho @willhonyc]

@BowTiedBiotech Our team at @In8bio has been saying GBM is a good place to start for solid tumors for years. #ASCO2025 - https://t.co/qnm9aWg9hA

[William Ho @willhonyc]

When we founded IN8bio, the idea was simple but ambitious: bring smarter, safer cell therapies to patients who need better options. Glioblastoma is one of the deadliest cancers, with virtually no progress in over two decades. Many told us not to bother because it was too hard, too small, too costly, or just because it's impossible. But for patients like Jim and their families, that’s not an acceptable answer.

Jim’s inspiring story shows what’s possible when science, perseverance, and courage come together. It’s a testament to innovation, to the vision of our scientific team, and to the dedication of physicians who refuse to give up.

We're still in the fight to find a path forward. Join us in a few weeks for an update at ASCO2025.

We’re proud of what our team and partners have accomplished, but the fight is far from over. Patients are still waiting.

This is why we do what we do.

[IN8bio @In8bio]

Jim was diagnosed with glioblastoma—one of the deadliest brain cancers.

Facing dismal survival rates and a standard of care that hasn’t changed in over 20 years, he joined an @In8bio trial using his immune system to fight back.

Jim's alive today—he is defying the odds. Watch his story.

#BrainTumorStrong #BrainTumorAwareness #GBM #BrainCancer #Immunotherapy #CancerZero

@SenJohnMcCain @mbsings @NBTStweets @BrainTumourOrg @theABTA @braintumourrsch @glioblastomaorg

[William Ho @willhonyc]

Can't disagree. Coming to this side it's baffling to me how some companies end up where they do. I've found the FDA to be generally straight forward and trying to help. We've been shocked at some competitor's whose guidance contradicts what we've been told directly by the Agency. This also just came out..."We believe in the letter and the spirit in right to try" This FDA does seem to be trying to bring down the regulatory barriers for "Dire" conditions. https://t.co/QTWsdQWWMK

[U.S. FDA @FDA]

"We want to focus the agency on cures and meaningful treatments." @DrMakaryFDA

[William Ho @willhonyc]

Exciting progress on our preclinical pipeline presented this week at AACR2025. Our lead T cell engager candidates, INB-619 (targeting CD19) and INB-633 (targeting CD33), have shown potent anti-cancer activity with some distinct advantages!

They effectively eliminated cancer cells in models without the secretion of potentially harmful inflammatory signals such as IL-6 that are associated with conventional engagers and drive significant toxicities like cytokine release syndrome.

We're optimistic about the potential of these candidates in the fight against cancer!

#CancerZero

[William Ho @willhonyc]

Thanks to @KarenJagoda for inviting me on her Empowered Patient Podcast to talk about @In8bio’s mission and how gamma-delta T cells are one of the most exciting frontiers in immunotherapy. We’re building smarter, and potentially safer and more effective therapies for cancer & autoimmune disease.

Full interview here: https://t.co/CZnrYlLySC

[William Ho @willhonyc]

@omnibusreader @chamath When there’s uncertainty and chaos in the market asset mangers sell equities and buy the safety of bonds. Typically treasuries which are the largest and considered the safest markets. Excess demand for treasuries pushes their prices up and yields (rates) down.